Conestat alfa

Generic name
Conestat alfa
Brand name
ATC Code
B06AC04

Conestat alfa

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

There is no specific data known for children (adolescents).

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Acute attack of hereditary angioedema resulting from C1-esterase inhibitor deficiency
  • Intravenous
    • ≥ 12 years
      • 50 U/kg/dose, once only. Max: 4.200 U/dose. If the response is insufficient, the daily dose can be repeated once. Maximum 2 doses in 24 hours..

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

OVERIGE HEMATOLOGISCHE MIDDELEN

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Enzymes
B06AA03
Drugs used in hereditary angioedema
B06AC02
B06AC05

Reference

  1. Pharming Groep N.V., SmPC Ruconest (EU/1/10/641/001) 24-05-2016, www.geneesmiddeleninformatiebank.nl

Changes

Therapeutic Drug Monitoring


Overdose